Clinical Trial

Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD

Study acronym: Not aplicable
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
1. To measure the ability of trans-resveratrol to influence the development of chronic heart failure (CHF) in women in the early postmenopausal period (1-4 years) with hypertension (HTN) and reduced bone mineral density (BMD). 2. To evaluate the safety of long-term use of trans-resveratrol in an amount of 500 mg per day. 3. To develop modern measures to influence the development of CHF in women of this group
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-13.
Trial Details
NCT Number NCT06828211
Lead Sponsor OMNIFARMA LLC
Conditions Heart Failure, Arterial Hypertension, Osteopenia, Menopause
Enrollment 80 participants
Start Date 2024-09-09
Primary Completion 2025-02-09 (estimated)
Study Completion 2025-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-19